US2021087278A1PendingUtilityA1
ANTI-cMET ANTIBODY
Est. expiryDec 2, 2028(~2.4 yrs left)· nominal 20-yr term from priority
A61K 33/243A61K 31/5377C07K 2317/77C07K 2317/56A61K 31/7068A61K 47/6813C07K 2317/53A61K 39/39558A61K 45/06C07K 2317/732C07K 2317/24A61K 2039/505A61K 31/555C07K 16/2863A61K 31/337C07K 2317/70C07K 2317/565A61K 39/3955C07K 2317/21C07K 2317/75C07K 2317/73C07K 2317/76A61K 31/517A61K 2039/507A61K 33/24
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
Claims
exact text as granted — not AI-modified1 - 33 . (canceled)
34 . A monoclonal antibody comprising a heavy chain comprising the amino acid sequence SEQ ID No. 4, and a light chain comprising the amino acid sequence SEQ ID No. 8, said antibody being further characterized in that it also comprises a hinge region comprising the amino acid sequence SEQ ID No. 22.
35 . The antibody of claim 34 , wherein the antibody is a chimeric antibody.
36 . The antibody of claim 34 , wherein the antibody is a human antibody.
37 . The antibody of claim 34 , wherein the antibody is a humanized antibody.
38 . The antibody of claim 34 , wherein the antibody comprises a human light chain constant region and a human heavy chain constant region.
39 . The antibody of claim 38 , wherein the human light chain constant region is of the IgG2 kappa isotype.
40 . A pharmaceutical composition comprising the antibody of claim 34 and a pharmaceutically acceptable vehicle.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.